The NEOPRISM-CRC clinical trial, led by researchers from UCL and UCLH, demonstrates that immunotherapy administered before surgery provides clinical benefit as first-line treatment for patients with advanced colorectal cancer. Patients with a specific type of bowel cancer who received a short course of pre-surgery immunotherapy remained cancer-free after nearly three years of follow-up. The trial used immunotherapy instead of traditional post-operative chemotherapy, offering an important alternative treatment approach for a disease that is increasingly affecting younger patients. The results suggest pre-surgery immunotherapy could replace chemotherapy for certain bowel cancer cases.
NEOPRISM-CRC trial results and patient outcomes
- ▪The NEOPRISM-CRC trial involved a short course of immunotherapy administered before surgery
- ▪Patients with a specific type of bowel cancer treated with pre-surgery immunotherapy in the NEOPRISM-CRC trial remained cancer-free after almost three years of follow-up
- ▪The NEOPRISM-CRC clinical trial was led by a team from UCL and UCLH
Shift from post-operative chemotherapy to pre-surgery immunotherapy
- ▪The NEOPRISM-CRC trial used pre-surgery immunotherapy instead of post-operative chemotherapy for treating a specific type of bowel cancer
- ▪Immunotherapy administered before surgery showed clinical benefit in advanced colorectal cancer as first-line treatment
Perspective of UCL and UCLH research team
- ▪The NEOPRISM-CRC trial demonstrates that immunotherapy offers a first-line treatment alternative to chemotherapy for advanced colorectal cancer
- ▪Pre-surgery immunotherapy can replace post-operative chemotherapy for certain bowel cancer patients according to the NEOPRISM-CRC trial results
Story comments
Loading comments…